XTL Biopharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2003
Selling, General & Admin	0.73	0.85	1	0.91	0.81	Upgrade
Research & Development	0.03	0.03	0.03	0.04	0.04	Upgrade
Operating Expenses	0.77	0.88	1.03	0.95	0.84	Upgrade
Operating Income	-0.77	-0.88	-1.03	-0.95	-0.84	Upgrade
Other Expense / Income	1.02	0.47	-1.47	2.01	-0.08	Upgrade
Pretax Income	-1.78	-1.35	0.44	-2.95	-0.76	Upgrade
Net Income	-1.78	-1.35	0.44	-2.95	-0.76	Upgrade
Shares Outstanding (Basic)	545	545	532	514	514	Upgrade
Shares Outstanding (Diluted)	545	545	616	514	514	Upgrade
Shares Change	-0.00%	-11.48%	19.71%	-	-	Upgrade
EPS (Basic)	-0.30	-0.20	0.10	-0.60	-0.10	Upgrade
EPS (Diluted)	-0.30	-0.20	-	-0.60	-0.10	Upgrade
Free Cash Flow	-0.71	-0.9	-1.05	-0.85	-0.91	Upgrade
Free Cash Flow Per Share	-0.13	-0.17	-0.20	-0.17	-0.18	Upgrade
EBITDA	-1.78	-1.35	0.44	-2.95	-0.76	Upgrade
EBIT	-1.78	-1.35	0.44	-2.95	-0.76	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).